<DOC>
	<DOCNO>NCT01805791</DOCNO>
	<brief_summary>A placebo control study two dos HMPL-004 patient active mild moderate ulcerative colitis ( UC ) , modify Mayo Score 4-10 endoscopy subscore 2-3 , take mesalamine ( equivalent ) concomitant medication . The objective evaluate efficacy safety HMPL-004 mesalamine ( mesalamine treatment failure ) . Efficacy measure comparison proportion patient treatment group attain clinical remission Week 8 compare placebo .</brief_summary>
	<brief_title>A Phase III Trial HMPL-004 Patients With Mild Moderate Active Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Patients must currently receive mesalamine ≥ 2.4 g/day ( equivalent ) least 6 week prior randomization stable dosage least 2 week prior enter screen phase study ensure stable dose establish least 2 week prior endoscopic procedure . Have active mild moderate ulcerative colitis define modify Mayo Score 410 , endoscopy score activity 23 point confirm centrally read colonoscopy ( within 2 week prior randomization . Minimum modify Mayo endoscopy score &gt; 2 time study colonoscopy . Age ≥ 18 year . Patients prior exposure HMPL004 . Have adequate renal , hepatic bone marrow function ( see exclusion criterion ) . All fertile male female subject must agree use one follow type contraception : abstinence , intrauterine device , implantable progesterone device , progesterone intramuscular injection , oral contraceptive start least one month prior visit one continue duration trial , contraceptive patch , condom spermicide . Show evidence personally sign date informed consent document indicate patient ( legally acceptable representative ) inform pertinent aspect trial 1 . Subjects intolerance adverse reaction mesalamine ( equivalent medication ) . 2 . Diagnosed Crohn 's Disease lesion fistulas granulomas biopsy note either history baseline endoscope , would suspicious Crohn 's disease , diagnosis indeterminate colitis . Subjects PSC ( Primary Sclerosing Cholangitis ) excluded.. 3 . Severe disease ulcerative colitis modify Mayo Clinic score 10 point baseline . 4 . Positive stool test pathogen sample take within previous 2 week prior study entry . 5 . Active Clostridium difficile ( C. diff ) infection . 6 . Use Inflammatory Bowel Disease relate herbal supplement include limited supplement contain andrographis probiotic two week prior study entry study . 7 . Toxic megacolon toxic colitis . 8 . Probable requirement intestinal surgery within 12 week start study medication . 9 . Receiving oral rectal steroid within 1 month prior study entry . 10 . Receiving rectal mesalamine within one week prior study entry . 11 . Receiving azathioprine , 6mercaptopurine , methotrexate , tacrolimus , cyclosporine , immunosuppressive therapy time screen within precede 6 week . 12 . Receiving antiTNFα agent infliximab , adalimumab , golimumab , certolizumab pegol time screen within precede 8 week . 13 . Receiving investigational drug biologics within 1 month five half life . 14 . Receiving antibiotic within 2 week study entry . 15 . Hemoglobin concentration &lt; 9 g/dl . 16 . WBC 3,000/cmm , platelet 100,000/cmm . 17 . SGOT , SGPT , alkaline phosphatase &gt; 2.5 upper limit normal . 18 . Serum creatinine &gt; 1.5 time upper limit normal . 19 . Significant concurrent medical disease include : active peptic ulcer disease ; uncompensated congestive heart disease ; myocardial infarction within last 12 month ; unstable angina pectoris ; uncontrolled hypertension ; pulmonary disease require oxygen therapy . 20 . Chronic Hepatitis B history Hepatitis C. 21 . Previous colonic surgery except simple polypectomy appendectomy . . 22 . History cancer within last 5 year resect cutaneous basal squamous cell carcinoma , situ cervical cancer . 23 . Patients history concurrent colonic dysplasia associate UC , except completely excise sporadic colorectal polyp . 24 . Women pregnant breast feeding . 25 . Patients know seropositive HIV , AIDS define illness , know immunodeficiency disorder . 26 . Patients history tuberculosis exposure tuberculosis , history chest Xray suspicious tuberculosis , unless confirm PPD negative latent tuberculosis previously treat . 27 . History alcohol drug abuse would interfere ability compliant study procedure . 28 . Known allergy plant Acanthaceae family . 29 . Unwillingness participate study . 30 . Any underlying medical condition Investigator 's opinion make administration study drug hazardous patient would obscure interpretation adverse event .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Ulcerative Colitis ,</keyword>
	<keyword>UC</keyword>
	<keyword>Patients</keyword>
	<keyword>active</keyword>
	<keyword>mild</keyword>
	<keyword>moderate</keyword>
</DOC>